Drug intelligence / Profile preview

N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is a small molecule belonging to the class of indolyl carboxylic acids and derivatives. It is not approved by the FDA or other major regulatory bodies and has no listed clinical trials or indications. The drug targets Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), though its specific mechanism of action is not detailed.

Other names: N-{[4-(2-Butyn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophanCHEMBL527018CHEMBL-527018CHEMBL 527018

Targets

ADAM17 (A disintegrin and metalloprotease 17)

Beyond the preview

Go deeper on N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan.

Explore the full profile